2015 American Transplant Congress
Infections After Alemtuzumab Induction: A Non Issue?
Transplant Institute, Tulane University, New Orleans, LA.
Background: Alemtuzumab is a powerful induction agent that depletes multiple lymphocyte cell lines resulting in leukopenia and/or neutropenia with concerns over infectious complications. This study…2015 American Transplant Congress
Reduced Intensity Immunosuppression Protocol Lowers Drug Costs and May Decrease Incidences of BK Viremia and Readmissions After Kidney and Kidney/Pancreas Transplant
Purpose: To evaluate the effects of a reduced intensity immunosuppression protocol on drug costs and rates of BK viremia and readmissions.Methods: In response to high…2015 American Transplant Congress
Effectiveness of Protocol-Driven Induction Therapy in Adult Kidney Transplant Recipients
Background: Induction therapy significantly improves graft outcomes in kidney transplantation, but the optimal agent based on patient characteristics and immunologic risk is unknown. While many…2015 American Transplant Congress
Early Use of Anti-Lymphocyte Antibody in Kidney Transplant Recipients With Delayed Graft Function Can Produce Desirable Post-Transplant Results
Department of Transplantation Surgery, Yonsei University Health System, Seoul, Republic of Korea.
Proper management of delayed graft function (DGF) is essential for successful post-transplant result in deceased donor kidney transplantation. We compared the effect of anti-lymphocyte antibody…2015 American Transplant Congress
Alemtuzumab Induction Is Protective Against Acute Rejection in Kidney Recipients With Subtherapeutic Tacrolimus Concentrations
Transplant Surgery, University of North Carolina Hospitals, Chapel Hill, NC.
Purpose: To determine the effect of attaining early therapeutic tacrolimus (TAC) trough concentrations on biopsy-proven acute rejection (BPAR) within 12 months post-transplantation in adult kidney…2015 American Transplant Congress
Induction of a Costimulation-Susceptible Repertoire: A Case for Depletional Prior to Belatacept
1Surgery, Duke University, Durham, NC; 2Transplant Center, Emory University, Atlanta, GA.
Belatacept offers highly specific costimulation blockade to prevent recipient alloimmune responses with reduced toxicity. However, when applied with nondepletional induction therapy belatacept-based regimens have higher…2015 American Transplant Congress
Effect of Induction in Renal Transplant Recipients Aged 70 and Over
Transplantation, Montefiore Medical Center, Bronx, NY.
While there is a significant survival advantage to transplanting patients 70 years of age and older versus staying on dialysis, it is unclear whether sensitized…2015 American Transplant Congress
Preliminary Results of a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab in a Pediatric Patient Population Undergoing Kidney Transplantation
Purpose: We report the outcomes from single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative day…2015 American Transplant Congress
Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients
1Transplant, Mayo Clinic, Jacksonville, FL; 2Pharmacy, Mayo Clinic, Jacksonville, FL.
Incidence of PVAN on protocol kidney biopsies with alemtuzumab induction is unknown.Methods:The 1-year risk of PVAN was retrospectively compared between 200 consecutive primary kidney recipients…2015 American Transplant Congress
Delayed Graft Function in Patients Receiving Alemtuzumab Induction Therapy
1The University of Toledo Medical Center, Toledo, OH; 2The Alliance for Paired Donation, Maumee, OH.
Alemtuzumab (Campath 1-H) is a humanized monoclonal antibody directed at the CD52 glycoprotein that is becoming more prevalent as a choice for induction. Delayed graft…
American Transplant Congress abstracts